Radar · Life Sciences in Toronto
Best Life Sciences Companies in Toronto, Canada
The 355 best Life Sciences companies in Toronto, Canada in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: ProMIS Neurosciences.
By Riya SenguptaFinancials
355companies tracked
$2.7Bdisclosed funding
0unicorns
134have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × TORONTO
Our analysis of 50 Life Sciences companies
$27.5b in tracked funding; 76% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
76%cloud-native stacks
2025funding peak (by rounds)
2013median founding year
45median Fliar Index™
260kcombined LinkedIn audience
47%of audience held by top 3
6companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in Toronto
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | ProMIS Neurosciences Antibody therapeutics and diagnostics for neurodegenerative diseases 37Funding top 10%Patents top 38%Moat top 38%Talent top 38% All 9 signals ▾Fundingtop 10% Patentstop 38% Moattop 38% Talenttop 38% Newstop 42% Innovationtop 47% Globalbottom 48% Techbottom 34% Marketbottom 24% Funding: Raised $247M across 37 rounds · 37 rounds over 20 yrs (1.9/yr) Patents: 78 patents matched (strict assignee match) · 29 filings since 2022 vs 39 in 2017-21 rank vs industry peers · Fliar Intelligence Index 37/100 | $247M | 4 mo ago | Public | 7 | Neil Cashman Co-Founder | 78 patents Therapeutic antibodies targeting misfolded neurodegenerative proteins (TDP-43, α‑synuclein, Aβ, SOD1). | — |
| 2 | Deep Genomics AI-powered platform for RNA biology to accelerate genetic therapy discovery 55AI top 22%Moat top 28%Funding top 29%Patents top 33% All 11 signals ▾AItop 22% Moattop 28% Fundingtop 29% Patentstop 33% Innovationtop 39% Talenttop 41% Marketbottom 49% Globalbottom 43% Techbottom 37% Growthbottom 35% Newsbottom 27% AI: Classified as an AI company · Holds AI/ML patents (G06N-family CPC) Moat: Editorial + unicorn rating 8/10 · IP moat: 92 patents rank vs industry peers · Fliar Intelligence Index 55/100 | $238M | 58 mo ago | Series C | 105 | Brendan Frey Co-Founder & Chief Innovation Officer | 92 patents AI-driven genomic variant analysis and therapeutic design for precision medicine | 6 job openings · 1 expansion |
| 3 | Cybin Provider of psychedelic therapeutics for psychiatric disorders 55Funding top 15%Tech top 42%Talent top 45%Moat top 48% All 6 signals ▾Fundingtop 15% Techtop 42% Talenttop 45% Moattop 48% Marketbottom 47% Globalbottom 37% Funding: Raised $230M across 6 rounds · 6 rounds over 6 yrs (1.0/yr) Tech: 34 technologies across 4/8 capability areas · Cloud: Cloudflare rank vs industry peers · Fliar Intelligence Index 55/100 | $230M | 11 mo ago | Public | 50 | Aaron Bartlone COO | — | — |
| 4 | Benchsci Developer of an AI platform for understanding disease biology 78AI top 20%Funding top 25%Talent top 28%Moat top 31% All 11 signals ▾AItop 20% Fundingtop 25% Talenttop 28% Moattop 31% Techtop 32% Innovationtop 35% Producttop 37% Markettop 45% Growthtop 45% Globalbottom 37% Newsbottom 32% AI: Classified as an AI company Funding: Raised $170M across 7 rounds · 7 rounds over 10 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 78/100 | $170M | 36 mo ago | Series D | 426 | Elvis Wianda Co-Founder | — | 1 launch |
| 5 | Titan Medical Developer of robotic surgical systems | $142M | 63 mo ago | Public | 48 | — | — | — |
| 6 | Geneseeq Providing personalised cancer treatment solutions based on patients genomic profile 55Talent top 28%Funding top 31%Moat top 40%Market bottom 49% All 5 signals ▾Talenttop 28% Fundingtop 31% Moattop 40% Marketbottom 49% Globalbottom 45% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated Funding: Raised $128M across 3 rounds · 3 rounds over 12 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 55/100 | $128M | 77 mo ago | Series D | — | Xiaonan Wang Co-Founder & CTO | — | — |
| 7 | Transition Therapeutics Small molecule therapeutics for CNS and metabolic diseases. | $113M | 143 mo ago | Acquired | 18 | — | 16 patents Peptide-based VIP therapeutics and vitamin‑B12/IMPDH inhibitor combos for metabolic, cardiac and antiviral diseases | — |
| 8 | Reunion Neuroscience Developer of therapeutics for mental health conditions | $103M | 29 mo ago | Acquired | 18 | — | 12 patents Design of tryptamine prodrugs and benzyltryptamine derivatives for CNS drug delivery | — |
| 9 | Trillium Therapeutics Developer of therapeutics for the treatment of cancer | $102M | 69 mo ago | Acquired | 33 | — | 180 patents Immune checkpoint therapies targeting CD47 with antibody and combination strategies | — |
| 10 | Notch Therapeutics Developer of stem-cell derived immune cell therapies | $100M | 25 mo ago | Series A | 90 | Shreya Shukla Founder | 18 patents Engineered T‑cell immunotherapies from stem cells and AI‑driven cellular outcome prediction | — |
| 11 | Entourage Health Producer, extractor, processor, and distributor of cannabis | $94M | 63 mo ago | Public | 211 | — | — | — |
| 12 | Xagenic Provider of point-of-care molecular diagnostics for infectious diseases | $59M | 131 mo ago | Series C | 45 | — | 50 patents Electrochemical biosensor platforms and precision current‑mode DACs for point‑of‑care diagnostics | — |
| 13 | Venus Developer of medical aesthetic devices for clinics | $47M | 36 mo ago | Public | — | Rajiv Desilva Chief Executive Officer | — | 2 launchs |
| 14 | Radiant Biotherapeutics Developer of therapeutics for cancer, auto-immune and infectious diseases 37Patents top 33%Funding top 34%Moat top 38%Innovation top 40% All 9 signals ▾Patentstop 33% Fundingtop 34% Moattop 38% Innovationtop 40% Techtop 41% Growthbottom 47% Globalbottom 40% Marketbottom 26% Newsbottom 18% Patents: 38 patents matched (strict assignee match) · 38 filings since 2022 vs 0 in 2017-21 Funding: Raised $43.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 37/100 | $43M | 21 mo ago | Series A | 11 | — | 38 patents Multispecific antibody therapeutics targeting TNF receptors and cytokine pathways | — |
| 15 | 3T Biosciences Developer of T-cell-based cancer immunotherapies to fight cancer | $40M | 45 mo ago | Series A | 33 | Leah Sibener Co-Founder | 27 patents High‑density EGFR/ErbB2‑targeted antibodies for cancer diagnostics and therapy | — |
| 16 | ACTO Provider of an AI and SaaS-based educational platform for the life science industry 40Funding top 29%Growth top 37%Moat top 39%Product top 40% All 7 signals ▾Fundingtop 29% Growthtop 37% Moattop 39% Producttop 40% Techtop 48% Globalbottom 43% Marketbottom 29% Funding: Raised $39.5M across 3 rounds · 3 rounds over 6 yrs (0.5/yr) Growth: 1 acquisition/expansion move in 24 mo · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 40/100 | $40M | 21 mo ago | Series B | 18 | — | — | — |
| 17 | iVexSol Developer of a platform for the production of vectors | $39M | 40 mo ago | Series A | 34 | Rodney Rietze Co-Founder & CEO | — | — |
| 18 | SQI Diagnostics Developer of multiplexed tests and automated systems for biological testing. | $37M | 42 mo ago | Public | 70 | — | 75 patents High‑throughput multiplex microarray immunoassay analysis and quantification platforms | — |
| 19 | Spectral Develops theranostic solutions for sepsis | $30M | 43 mo ago | Public | 32 | Chris Seto Chief Executive Officer | — | — |
| 20 | Conavi A catheter-based ultrasound system for cardiac imaging 48Funding top 24%Growth top 38%News top 38%Partners top 40% All 9 signals ▾Fundingtop 24% Growthtop 38% Newstop 38% Partnerstop 40% Moattop 48% Talentbottom 49% Marketbottom 48% Techbottom 41% Globalbottom 29% Funding: Raised $27.7M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) Growth: 2 acquisition/expansion moves in 24 mo · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 48/100 | $28M | 5 mo ago | Public | 76 | Aman Thind Co-founder and Chief Technology Officer | — | 1 launch · 2 awards |
| 21 | Xandar Kardian Provider of radar-based sensors for detecting human presence | $24M | 54 mo ago | Series A | 36 | Sung Cho Co-Founder | — | — |
| 22 | Cyclica AI platform for supporting drug discovery research | $21M | 43 mo ago | Acquired | 56 | Jason Mitakidis Founder | 32 patents AI-powered computational drug discovery and proteome-wide ligand docking platforms. | — |
| 23 | Revive Therapeutics Developer of therapeutics to treat rare and infectious diseases 27Product top 24%Moat top 32%Funding top 36%Patents top 42% All 10 signals ▾Producttop 24% Moattop 32% Fundingtop 36% Patentstop 42% Innovationtop 44% Growthtop 48% Techbottom 48% Newsbottom 43% Globalbottom 31% Marketbottom 16% Product: 2 distinct product lines · Company stage: Public Moat: Editorial + unicorn rating 5/10 · IP moat: 24 patents rank vs industry peers · Fliar Intelligence Index 27/100 | $17M | 10 mo ago | Public | 3 | — | 24 patents Neuroprotective and anti‑infective therapeutics repurposing bucillamine and psilocybin | — |
| 24 | MolecuLight Provider of point of care device for wound assessment | $16M | 17 mo ago | Series D | 49 | — | 77 patents Point‑of‑care fluorescence and multimodal medical imaging devices with AI analysis | 1 launch |
| 25 | Grey Matter Neurosciences Developer of medical devices for neurological disease treatment | $14M | 16 mo ago | Seed | — | Jeffrey Coull Founder & CEO | — | — |
| 26 | Profound Medical Developer of image guided prostate ablation system for cancer treatment 80Patents top 25%Funding top 31%Innovation top 33%Tech top 34% All 12 signals ▾Patentstop 25% Fundingtop 31% Innovationtop 33% Techtop 34% Moattop 35% Growthtop 36% Newstop 39% Markettop 40% Fin. healthtop 41% Globaltop 44% AItop 45% Partnerstop 45% Patents: 171 patents matched (strict assignee match) · 60 filings since 2022 vs 85 in 2017-21 Funding: Raised $12.9M across 11 rounds · 11 rounds over 18 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 80/100 | $13M | 5 mo ago | Public | 131 | — | 171 patents Patents concentrated in health & consumer products | — |
| 27 | Intrepid Labs Developer of drug formulation science to accelerate the development of therapeutics 35Market bottom 49%Funding bottom 49%Talent bottom 49%Global bottom 45% All 4 signals ▾Marketbottom 49% Fundingbottom 49% Talentbottom 49% Globalbottom 45% Funding: Raised $11.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $11M | 13 mo ago | Seed | — | Christine Allen Co-Founder and CEO | — | — |
| 28 | VentriPoint Heart analysis system 62News top 18%Product top 24%Growth top 25%Partners top 32% All 10 signals ▾Newstop 18% Producttop 24% Growthtop 25% Partnerstop 32% Fundingtop 36% Globaltop 37% Techtop 44% Innovationtop 47% Moattop 48% Marketbottom 45% News: 9 BI events in 12 mo (of 46 tracked, 7 types) · +350% YoY Product: 1 product launch event in 12 mo · 12 distinct product lines rank vs industry peers · Fliar Intelligence Index 62/100 | $9M | 16 mo ago | Public | — | — | — | — |
| 29 | Psyence Developer of psychedelic therapeutics for mental health disorders 45News top 26%Growth top 36%Funding top 40%Global top 41% All 7 signals ▾Newstop 26% Growthtop 36% Fundingtop 40% Globaltop 41% Talenttop 49% Marketbottom 43% Techbottom 36% News: 10 BI events in 12 mo (of 25 tracked, 10 types) · +25% YoY Growth: Web rank 10,000,000 → 50,000,000 YoY · 3 acquisition/expansion moves in 24 mo rank vs industry peers · Fliar Intelligence Index 45/100 | $9M | 12 mo ago | Public | — | Alan Friedman Co-Founder | — | — |
| 30 | Paradox Immunotherapeutics Developer of immunotherapeutics for the treatment of rare diseases | $7M | 15 mo ago | Series A | 9 | Yulong Sun Co-Founder | 5 patents Therapeutic monoclonal antibodies targeting conformational epitopes of lambda immunoglobulin light chains | — |
| 31 | Edesa Biotech Developer of topical therapeutics for dermatological and gastrointestinal diseases | $7M | 16 mo ago | Public | 16 | Par Nijhawan Founder & CEO | 8 patents Peptide-based therapeutics for vitiligo and acute respiratory distress syndrome treatment | — |
| 32 | Pattern Pharma Developer of immunotherapies to treat cancers and infectious diseases | $7M | 14 mo ago | Series A | 5 | — | — | — |
| 33 | BirchBioMed Developer of anti-scarring drugs and autoimmune therapies | $6M | 11 mo ago | Series A | 6 | — | 16 patents Topical small‑molecule anti‑aging and scar‑reduction dermatology formulations | — |
| 34 | Telo Genomics Developer of non-invasive prognostic and diagnostic applications that improve disease treatment 37Moat top 31%News top 38%Talent top 39%Partners top 40% All 11 signals ▾Moattop 31% Newstop 38% Talenttop 39% Partnerstop 40% Patentstop 43% Fundingtop 44% AItop 45% Growthtop 48% Innovationbottom 48% Globalbottom 33% Marketbottom 24% Moat: Editorial + unicorn rating 6/10 · IP moat: 9 patents News: 9 BI events in 12 mo (of 37 tracked, 6 types) · -25% YoY rank vs industry peers · Fliar Intelligence Index 37/100 | $5M | 3 mo ago | Public | 6 | Sherif Louis CEO | 9 patents Diagnostic assays for smoldering multiple myeloma using nucleic‑acid biomarkers | — |
| 35 | Theralase Technologies Super pulsed cold laser technology for musculoskeletal pain | $5M | 19 mo ago | Public | 14 | Roger Dumoulin-White President and Chief Executive Officer | 6 patents Patents concentrated in chemistry & materials | — |
| 36 | ProteinQure Provider of computational protein drug design platform 53Talent top 28%AI top 30%Innovation top 36%Product top 36% All 10 signals ▾Talenttop 28% AItop 30% Innovationtop 36% Producttop 36% Moattop 37% Patentstop 38% Fundingtop 46% Techbottom 45% Globalbottom 40% Marketbottom 29% Talent: Analyst team rating 4/5 · 4 named leaders on record AI: Classified as an AI company · Product described with: artificial intelligence rank vs industry peers · Fliar Intelligence Index 53/100 | $4M | 12 mo ago | Series A | 18 | Tomas Babej Cofounder and Chief Technology Officer | 9 patents Protein therapeutics targeting the sortilin receptor and natriuretic peptide delivery systems | 2 job openings |
| 37 | Acorn Provider of stem cell biobanking services | $3M | 28 mo ago | Series A | 19 | Patrick Pumputis Co-Founder & CSO | — | — |
| 38 | VAE Labs Internet-first brand offering energy sprays | $2M | 17 mo ago | Series A | 5 | Chaim Weinerman Founder | — | — |
| 39 | Proteocyte Provider of diagnostic test to predict risk of developing cancers | $2M | 13 mo ago | Series A | 5 | — | — | 2 launchs |
| 40 | Mesosil Developer of antimicrobial materials | $2M | 24 mo ago | Seed | 5 | — | 6 patents Controlled ion and metal‑oxide release systems for dental and medical therapeutics | — |
| 41 | Lactiga Developer of immunotherapies to treat infectious diseases | $2M | 16 mo ago | Seed | 5 | Viraj Mane Co-Founder | 8 patents Polyclonal antibody therapeutics for RSV and oral breast‑milk‑derived immunoglobulin delivery | — |
| 42 | Steadiwear Designer & manufacturer of healthcare gloves 29Growth top 35%Moat top 38%Tech top 42%Funding bottom 49% All 10 signals ▾Growthtop 35% Moattop 38% Techtop 42% Fundingbottom 49% Talentbottom 49% Productbottom 47% Innovationbottom 40% Globalbottom 39% Patentsbottom 37% Marketbottom 17% Growth: Fresh capital in last 24 mo Moat: Editorial + unicorn rating 4/10 · IP moat: 8 patents rank vs industry peers · Fliar Intelligence Index 29/100 | $1M | 8 mo ago | Seed | 6 | Mark Elias Co-Founder & CEO | 8 patents Wearable tremor‑damping devices for involuntary hand motion control in medical applications | — |
| 43 | EMN Developer of clinical-grade nutrition products | $1M | 17 mo ago | Series A | 10 | Timothy Ormond Co-Founder | — | 1 launch |
| 44 | Satellos Bioscience Developer of small molecule drugs for rare diseases | $1M | 17 mo ago | Public | 3 | Michael Rudnicki Co-Founder | 6 patents Patents concentrated in chemistry & materials | — |
| 45 | Ostia Sciences Developer of microbes for fighting infectious diseases and enhancing immune function | $740K | 11 mo ago | Seed | — | Michael Glogauer Co-Founder | — | — |
| 46 | Quantum Biopharma Developer of therapies for neurodegenerative and neuropsychiatric diseases | $500K | 7 mo ago | Public | — | Anthony Durkacz Co-Founder | — | 1 launch |
| 47 | Clincove AI-powered clinical trial management platform designed to streamline and accelerate Phase I–III studies 40AI top 45%Talent top 45%Funding bottom 41%Global bottom 33% All 4 signals ▾AItop 45% Talenttop 45% Fundingbottom 41% Globalbottom 33% AI: Product described with: ai-powered Talent: 2 named leaders on record rank vs industry peers · Fliar Intelligence Index 40/100 | $500K | 8 mo ago | Seed | — | Michael Sousa Chief Technology Officer | — | 2 launchs |
| 48 | Neural Therapeutics Developer of ethnobotanical drug for neurological disorder | $495K | 15 mo ago | Public | 2 | Ian Campbell Chief Executive Officer | — | — |
| 49 | GEFION CANADA Healthcare company offering cannabinoid based products | $300K | 22 mo ago | Seed | — | — | — | — |
| 50 | Thiogenesis Developer of thiol-active drugs for the treatment of pediatric patients | $252K | 10 mo ago | Seed | — | Patrice Rioux Chief Executive Officer | — | — |
Top 12 Life Sciences companies in Toronto
#1
Public · Toronto, Ontario · founded 2004 · 7 employees$247.3Mraised▾
Public · Toronto, Ontario · founded 2004 · 7 employees
ProMIS Neurosciences discovers and develops precision therapeutics and companion diagnostics for early detection and effective treatment of neurodegenerative diseases, in particular, Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). The company utilizes its computational discovery platform, ProMIS, to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. It owns the exclusive rights to the Genus patent relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic directed against this target.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Funding
top 10%Patents
top 38%Moat
top 38%Talent
top 38%News
top 42%Innovation
top 47%Funding: Raised $247M across 37 rounds · 37 rounds over 20 yrs (1.9/yr) · Last round Post IPO (Jan 2026)
Patents: 78 patents matched (strict assignee match) · 29 filings since 2022 vs 39 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 5/10 · IP moat: 78 patents · 10 curated direct competitors tracked
Audience (LinkedIn): 3k LinkedIn followers
Funding rounds
- Jan 2026Post IPO$175M
- Jul 2025Post IPO$9.2M
- Sep 2023Post IPO$14.9M
- Oct 2022Post IPO$7.5M
Founders & team
Investors
The Kraft Group, Nosterra, Ally Bridge Group, Janus Henderson Investors, Deep Track Capital, Great Point Partners
Tech stack
Apache Http ServerBootstrapFancyboxGodaddyGoogle AnalyticsHcaptcha
#2
Public · Toronto, Ontario · founded 2002 · 50 employees$229.7Mraised▾
Public · Toronto, Ontario · founded 2002 · 50 employees
Provider of psychedelic therapeutics for psychiatric disorders. The product pipeline includes CYB003 a deuterated psilocin for the adjunctive treatment of major depressive disorderCYB004 deuterated dimethyltryptamine compound targeting generalized anxiety disorder and CYB005 aphenethylamine derivative treating neuroinflammation.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Funding
top 15%Tech
top 42%Talent
top 45%Moat
top 48%Market
bottom 47%Global
bottom 37%Funding: Raised $230M across 6 rounds · 6 rounds over 6 yrs (1.0/yr) · Last round Post IPO (Jun 2025)
Tech: 34 technologies across 4/8 capability areas · Cloud: Cloudflare · Devops: Nginx
Talent: 2 named leaders on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 31k LinkedIn followers — 12.0% of this cohort's audience
Funding rounds
- Jun 2025Post IPO$50M
- Mar 2024Post IPO$150M
- Mar 2022Post IPO$317.1K
- Feb 2021Post IPO—
Founders & team
Investors
Deep Track Capital, Hightrailcapital, Noetic Psychedelic Fund, JLS Fund, Innovating Capital, The Conscious Fund
#3
Public · Toronto, Ontario · founded 2007 · 76 employees$27.7Mraised▾
Public · Toronto, Ontario · founded 2007 · 76 employees
A catheter-based ultrasound system for cardiac imaging. The company has developed, Foresight ICE System, a catheter-based ultrasound system capable of providing both 2D and 3D ultrasound images of cardiac anatomy around the circumference of the catheter's tip.
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Funding
top 24%Growth
top 38%News
top 38%Partners
top 40%Moat
top 48%Talent
bottom 49%Funding: Raised $27.7M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) · Last round Post IPO (Jan 2026)
Growth: 2 acquisition/expansion moves in 24 mo · Fresh capital in last 24 mo
News: 14 BI events in 12 mo (of 41 tracked, 11 types) · -18% YoY · 3 high-value events (IPO/M&A/funding/contracts) in 12 mo
Audience (LinkedIn): 9k LinkedIn followers — 3.6% of this cohort's audience
Activity (LinkedIn): 1 product launches · 2 awards announced in 12 mo
Funding rounds
- Jan 2026Post IPO$700K
- Apr 2025Post IPO$15.5M
- Oct 2024Series B$7.7M
- Dec 2021Series B$20M
Founders & team
Investors
FedDev Ontario, Titan Medical, MaRS Discovery District, CPOINT Capital, Tivona Capital, Ontario Brain Institute
Tech stack
GodaddyGoogle CloudGoogle Cloud CdnGoogle Font ApiHttp/3Open Graph
#4
Public · Toronto, Ontario · founded 2008 · 131 employees$12.9Mraised▾
Public · Toronto, Ontario · founded 2008 · 131 employees
Developer of image guided prostate ablation system for cancer treatment. The company uses proprietary technology and provide TULSA-PRO is an AI-powered, MRI-guided, incision-free robotic ablation system for the ablation of prostate tissue.
Fliar Intelligence Index™ 80how this company ranks against its industry peers
Patents
top 25%Funding
top 31%Innovation
top 33%Tech
top 34%Moat
top 35%Growth
top 36%Patents: 171 patents matched (strict assignee match) · 60 filings since 2022 vs 85 in 2017-21 · Latest publication 2026
Funding: Raised $12.9M across 11 rounds · 11 rounds over 18 yrs (0.6/yr) · Last round Post IPO (Dec 2025)
Innovation: 171 patents (top 16% of patent-holders) · 60 filings since 2022 vs 85 in 2017-21 · Deep-tech classification: Tech Hardware
Audience (LinkedIn): 18k LinkedIn followers — 6.9% of this cohort's audience
Funding rounds
- Dec 2025Post IPO$6.5M
- Jan 2024Post IPO—
- Jul 2020Post IPO$46M
- Mar 2018Post IPO$34.5M
Investors
BDC, Genesys Capital, FedDev Ontario, Knight Therapeutics, Stifel, Cormark Securities
Tech stack
Amazon CloudfrontAmazon Web ServicesApache Http ServerBootstrapChart.JsCloudflare
#5
Public · Toronto, Ontario · founded 2011 · 6 employees$5.5Mraised▾
Public · Toronto, Ontario · founded 2011 · 6 employees
Developer of non-invasive prognostic and diagnostic applications that improve disease treatment. The company has a proprietary technology that uses a quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease-associated genetic instability. It is developing Telo-MM application to provide e information to medical professionals in the treatment of Multiple Myeloma.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Moat
top 31%News
top 38%Talent
top 39%Partners
top 40%Patents
top 43%Funding
top 44%Moat: Editorial + unicorn rating 6/10 · IP moat: 9 patents
News: 9 BI events in 12 mo (of 37 tracked, 6 types) · -25% YoY · 4 high-value events (IPO/M&A/funding/contracts) in 12 mo
Talent: 1 named leader on record · 1 C-suite/founder profile curated · 5 leadership moves in 12 mo
Audience (LinkedIn): 845 LinkedIn followers
Funding rounds
- Mar 2026Post IPO—
- Dec 2024Post IPO$1.8M
- May 2023Post IPO$2M
- Jul 2021Post IPO$1.7M
Founders & team
#6
Public · Toronto, Ontario · founded 2012 · 3 employees$16.8Mraised▾
Public · Toronto, Ontario · founded 2012 · 3 employees
Developer of therapeutics to treat rare and infectious diseases. Its lead product Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) helps in treating infectious diseases, including COVID-19, influenza, and others. Also has psilocybin for multiple indications.
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Product
top 24%Moat
top 32%Funding
top 36%Patents
top 42%Innovation
top 44%Growth
top 48%Product: 2 distinct product lines · Company stage: Public
Moat: Editorial + unicorn rating 5/10 · IP moat: 24 patents
Funding: Raised $16.8M across 11 rounds · 11 rounds over 13 yrs (0.8/yr) · Last round Post IPO (Aug 2025)
Audience (LinkedIn): 1k LinkedIn followers
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Aug 2025Post IPO$110.7K
- Apr 2025Post IPO$120.2K
- Jan 2024Post IPO$1.6M
- Jan 2023Post IPO$4.3M
Investors
EMD Financial, Planet Ventures
Tech stack
Apache Http ServerCloudflareCloudflare Bot ManagementDiviGodaddyGoogle Analytics
#7
Public · Toronto, Ontario · founded 1997$8.6Mraised▾
Public · Toronto, Ontario · founded 1997
Developer of psychedelic therapeutics for mental health disorders. The company's psilocybin drug candidates reduce the symptoms of psychological trauma, PTSD, depression, anxiety, stress, and addiction.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
News
top 26%Growth
top 36%Funding
top 40%Global
top 41%Talent
top 49%Market
bottom 43%News: 10 BI events in 12 mo (of 25 tracked, 10 types) · +25% YoY · 2 high-value events (IPO/M&A/funding/contracts) in 12 mo
Growth: Web rank 10,000,000 → 50,000,000 YoY · 3 acquisition/expansion moves in 24 mo · Fresh capital in last 24 mo
Funding: Raised $8.6M across 6 rounds · 6 rounds over 5 yrs (1.2/yr) · Last round Post IPO (Jun 2025)
Audience (LinkedIn): 2k LinkedIn followers
Funding rounds
- Jun 2025Post IPO$441.1K
- Dec 2024Post IPO$2M
- Aug 2023Post IPO$93.5K
- Apr 2023Post IPO$2.2M
Founders & team
Tech stack
Apache Http ServerBootstrapContact Form 7GodaddyGoogle AnalyticsGoogle Font Api
#8
Seed · Toronto, Ontario · founded 2023$11Mraised▾
Seed · Toronto, Ontario · founded 2023
Developer of drug formulation science to accelerate the development of therapeutics. The proprietary technology platform, VALIANT, enables the design and optimization of fully optimized formulations of drugs by improving the properties and performance of therapeutic molecules.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Market
bottom 49%Funding
bottom 49%Talent
bottom 49%Global
bottom 45%Funding: Raised $11.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) · Last round Seed (May 2025)
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 6k LinkedIn followers — 2.2% of this cohort's audience
Funding rounds
- May 2025Seed$7M
- 2023Seed$4M
Founders & team
Investors
AVANT BIO, Radical Ventures, Propagator Ventures
#9
Series A · Toronto, Ontario · founded 2014 · 6 employees$5.9Mraised▾
Series A · Toronto, Ontario · founded 2014 · 6 employees
Developer of anti-scarring drugs and autoimmune therapies. It offers a lead candidate AI-001 which uses a single dose of allogeneic cells injected into the patient for treatment of Type-1 Diabetes, Psoriasis and Alopecia.
Funding rounds
- Jun 2025Series A$2.5M
- Oct 2021Series A$596K
- Feb 2020Series A$5.3M
#10
Series D · Toronto, Ontario · founded 2013 · 49 employees$15.7Mraised▾
Series D · Toronto, Ontario · founded 2013 · 49 employees
Provider of point of care device for wound assessment. The company's first product, the i:X, is a hand-held fluorescence imaging device for visualizing bacterial presence and distribution in the skin and chronic wounds. i:X launched in 2015. Founded by Dr. Ralph Da Costa.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 6k LinkedIn followers — 2.4% of this cohort's audience
Activity: 1 product launches announced in 12 mo
Funding rounds
- Jan 2025Series D$27.5M
- Aug 2024Series C$11.7M
- Aug 2022Conventional Debt—
- Jan 2022Conventional Debt$10M
Investors
BDC, iGan Partners, Export Development Canada, Prosegur, Azahar, SWK Holdings
Tech stack
Amazon S3Amazon Web ServicesApache Http ServerApple Icloud MailBootstrapCloudflare
#11
Series A · Toronto, Ontario · founded 2018 · 5 employees$6.9Mraised▾
Series A · Toronto, Ontario · founded 2018 · 5 employees
Pattern Pharma is developing immunotherapies to treat cancers and infectious diseases. Its lead candidate, PAR-1 modulates the innate immune system (dendritic cells, macrophages, and NK cells). The candidate is PRR (Pattern Recognition Receptor) TLR-4 agonist and is being tested a stand-alone product and in combination therapy.
Funding rounds
- Apr 2025Series A$798.5K
- Feb 2024Series A$275K
- May 2021Series A$4.1M
- May 2021Seed$1.6M
Investors
MaRS Discovery District
#12
Series B · Toronto, Ontario · founded 2014 · 18 employees$39.5Mraised▾
Series B · Toronto, Ontario · founded 2014 · 18 employees
Provider of an AI and SaaS-based educational platform for the life science industry. The company has developed a digital platform with learning tools like SALESFitness which is a product that provides trading in clinical sales, MARKETINGFitness a centralized tool for life science marketing of new launches, MSLFitness provides engaging learning experiences and more. There are features for remote video coaching, user engagement tools, and AI-assisted tools for performance tracking.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Funding
top 29%Growth
top 37%Moat
top 39%Product
top 40%Tech
top 48%Global
bottom 43%Funding: Raised $39.5M across 3 rounds · 3 rounds over 6 yrs (0.5/yr) · Last round Series B (Sep 2024)
Growth: 1 acquisition/expansion move in 24 mo · Fresh capital in last 24 mo
Moat: Editorial + unicorn rating 7/10 · 9 curated direct competitors tracked
Audience (LinkedIn): 6k LinkedIn followers — 2.1% of this cohort's audience
Funding rounds
- Sep 2024Series B$10M
- Jul 2022Series B$18M
- Aug 2020Series A$11.5M
Investors
Resolve Growth Partners, Panache Ventures, Salesforce Ventures, Questa Capital, MaRS IAF, Graphite Ventures
Tech stack
CloudflareCloudflare Bot ManagementCookieyesCore-JsElementorFacebook Pixel
Funding & investor landscape
$2.7Btotal disclosed funding
114companies funded
396disclosed rounds
0rounds last 90 days
Most active investors
Notable founders
Neil Cashman
Co-Founder · ProMIS Neurosciences
Elliot Goldstein Md
President & CEO · ProMIS Neurosciences
Aaron Bartlone
COO · Cybin
Sarah Hamilton
Director Financial Operations & Strategic Operations · Cybin
Aman Thind
Co-founder and Chief Technology Officer · Conavi
Sherif Louis
CEO · Telo Genomics
Alan Friedman
Co-Founder · Psyence
Christine Allen
Co-Founder and CEO · Intrepid Labs
Jeffrey Coull
Founder & CEO · Grey Matter Neurosciences
Tomas Babej
Cofounder and Chief Technology Officer · ProteinQure
Lucas Siow
Co-Founder & CEO · ProteinQure
Mark Elias
Co-Founder & CEO · Steadiwear
Prism market signals · Canada · country-scoped Prism corpus, 188,258 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH IN TORONTO · Health & Bio
How research on Biotechnology in Toronto is moving
A read on the academic research around Biotechnology in Toronto — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 63 papers.
University of Toronto and allied hospitals lead Toronto's biotechnology research—focused on CRISPR, RNA, and nanoparticle delivery—with a cautiously optimistic, advancement-driven tone amid growing recent output.
63 papers · stance +0.49 · 40% breakthrough · 18% concern
top institutions
- University of Toronto61
- Toronto General Hospital2
- Toronto Centre for Phenogenomics1
- Toronto Metropolitan University1
leading researchers
Warren C. W. Chan · Amirhossein Babalhavaeji · Andrew A. Beharry · Benjamin H. Lok · Carl Walkey · Geoffrey Liu
prism intelligence · tone & topics
95% positive · 2% critical tone
PharmaceuticalsMedical ResearchHealthBiologyGeneticsClinical Trials
▲
Breakthroughs22 · 35%
▲ 25%→38% share
▲1.5× share momentum0 median citations73% since 2021mostly empirical
Genome and RNA-binding protein research is rising, lifting Breakthroughs field-share from 25% to 38% across 63 Toronto biotech papers.
rising sub-themes (early→recent)
- Genome2
- Mutant2
- RNA-binding protein2
- Gene2
- Transcription factor2
Landmark Speckle variance detection of microvasculature using swept-source optical coherence tomography · 697 cites
◆
Advancements23 · 37%
▲ 25%→45% share
▲1.8× share momentum0 median citations83% since 2021mostly empirical
Advancements field-share surged 25% to 45%, driven by newly emerging Virus, Cell, and Cell culture sub-topics each adding 3–4 papers.
rising sub-themes (early→recent)
- Virus4
- Cell4
- Cell culture3
- Gene3
- Ethylene glycol2
Newly emergingVirus 0→4 · Cell 0→4 · Cell culture 0→3
Landmark Mediating Tumor Targeting Efficiency of Nanoparticles Through Design · 1,476 cites
▼
Concerns10 · 16%
▼ 31%→7% share
▼0.2× share momentum452 median citations30% since 2021mostly empirical
Concerns field-share collapsed from 31% to 7% despite Nanoparticle and In vivo sub-topics each logging 3 rising papers.
rising sub-themes (early→recent)
- Nanoparticle3
- In vivo3
- Nanotechnology2
- Toxicity2
- Quantum dot2
Landmark Growth Factors, Matrices, and Forces Combine and Control Stem Cells · 2,597 cites
PATENT MOMENTUM · Toronto
Who's building biotechnology IP in Toronto
LS Travel Retail North America dominates Toronto's biotechnology patent activity with all 4 filings, though the sparse, intermittent output across years signals a cooling or stagnant trend.
4 patents1 companiespeak 1/yr
filing momentum (YoY)
top patenters
- ls travel retail north america4toronto
Common questions
How many Life Sciences companies are there in Toronto, Canada?
Radar tracks 355 indexable Life Sciences companies headquartered in Toronto, Canada that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in Toronto, Canada?
The Life Sciences companies in Toronto, Canada on this list have raised a combined $2.7B in disclosed equity funding across 114 funded companies.
Which is the highest-funded Life Sciences company in Toronto, Canada?
ProMIS Neurosciences is the highest-funded Life Sciences company in Toronto, Canada, with $247.3M in disclosed equity funding.
How many Life Sciences companies in Toronto, Canada are funded?
114 of the 355 Life Sciences companies in Toronto, Canada on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in Toronto, Canada?
None of the Life Sciences companies in Toronto, Canada on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in Toronto, Canada Life Sciences companies?
The most active investors in Toronto, Canada Life Sciences companies on this list include UTEST, Ontario Centre of Innovation, Ontario Brain Institute, MaRS Discovery District, TIAP.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.